在动荡的市场环境中，BYU股价已跌至52周低点，仅达到0.23美元的价格水平。这一显著下跌反映了该公司的一个更广泛趋势，过去一年其价值已大幅缩水。投资者目睹了该股票价值一年内惊人的变化，China Commercial经历了高达-94.83%的急剧下降。这一急剧下跌凸显了该公司在竞争激烈且快速变化的经济环境中面临的挑战，使市场观察者密切关注BYU的表现，寻找稳定或进一步下跌的迹象。 在其他近期新闻 ...

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...

Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...

The US Food and Drug Administration (FDA) yesterday published the guidance for industry, “Requests for Reconsideration at the ...